DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Newbridge Financial Services Group Inc.

Newbridge Financial Services Group Inc. lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCMFree Report) by 37.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,930 shares of the medical device company’s stock after selling 1,134 shares during the period. Newbridge Financial Services Group Inc.’s holdings in DexCom were worth $268,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Capital World Investors boosted its position in DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Norges Bank purchased a new stake in shares of DexCom in the fourth quarter valued at $540,178,000. Artisan Partners Limited Partnership lifted its position in shares of DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after acquiring an additional 3,672,471 shares in the last quarter. Capital Research Global Investors lifted its position in shares of DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after acquiring an additional 2,695,296 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of DexCom in the fourth quarter valued at $231,773,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on DXCM. Citigroup upped their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Canaccord Genuity Group increased their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. UBS Group increased their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada assumed coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $141.67.

View Our Latest Analysis on DXCM

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the transaction, the executive vice president now owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 629 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the sale, the executive vice president now directly owns 68,212 shares in the company, valued at approximately $8,611,765. The disclosure for this sale can be found here. Insiders sold a total of 186,641 shares of company stock worth $25,217,707 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

DexCom Stock Up 0.1 %

Shares of DXCM stock traded up $0.15 during trading hours on Tuesday, reaching $130.84. The company had a trading volume of 1,763,165 shares, compared to its average volume of 2,896,107. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a market capitalization of $52.03 billion, a P/E ratio of 84.41, a price-to-earnings-growth ratio of 2.24 and a beta of 1.23. The stock’s fifty day simple moving average is $133.12 and its 200 day simple moving average is $123.94.

DexCom (NASDAQ:DXCMGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. As a group, sell-side analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

DexCom Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Stories

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.